PM8002/BNT327 plus nab-paclitaxel demonstrated “clinically meaningful” activity in advanced TNBC, according to researchers.

NovoCure's TTFields therapy, combined with standard chemotherapy, improves overall survival in advanced pancreatic cancer.

The ARMANI trial, a phase 3 multicentre study reported by Giovanni Randon and colleagues,1 investigates the effect of switch ...

Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a ...

Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable ...

On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial ...

Th e GINECO trial explored the combination of trastuzumab with paclitaxel and carboplatin in patients with resistant AOC (< 6 months) and HER2 gene amplification. Patients and Methods: A total of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...

Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor ...

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...